Crohn’s disease, Ulcerative colitis research hub

A 14-Week Phase 2b, RandomizEd, Double-BLind, Dose-Ranging Study to Determine the PharmacokInetics, Efficacy, Safety, and Tolerability of TEV-48574 in Adult PatiEnts with Moderate to Severe Ulcerative Colitis or Crohn’s Disease (RELIEVE UCCD)

This study is testing a new medicine called TEV-48574 for adults with moderate to severe Crohn's disease or ulcerative colitis. It aims to see how well it works, if it's safe, and how the body handles it, comparing it to a dummy medicine.